Cytokinetics, Incorporated (CYTK)
Market Cap | 6.99B |
Revenue (ttm) | 7.53M |
Net Income (ttm) | -526.24M |
Shares Out | 104.58M |
EPS (ttm) | -5.45 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 781,172 |
Open | 65.89 |
Previous Close | 65.57 |
Day's Range | 65.68 - 67.45 |
52-Week Range | 25.98 - 110.25 |
Beta | 0.68 |
Analysts | Strong Buy |
Price Target | 80.53 (+20.52%) |
Earnings Date | May 8, 2024 |
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that i... [Read more]
Financial Performance
In 2023, Cytokinetics's revenue was $7.53 million, a decrease of -92.04% compared to the previous year's $94.59 million. Losses were -$526.24 million, 35.3% more than in 2022.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for CYTK stock is "Strong Buy." The 12-month stock price forecast is $80.53, which is an increase of 20.52% from the latest price.
News
Cytokinetics to Announce First Quarter Results on May 8, 2024
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM...
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and Function Treatment with Aficamten for 48 Weeks is...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 29, 2024 it granted stock options to purchase an aggregate of 78...
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pa...
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73rd Annual Scientifi...
Cytokinetics to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor confere...
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and t...
Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials
Grant Funding Provided by Cytokinetics to Each Organization to Help Increase Clinical Trial Engagement Among Historically Underrepresented Groups Grant Funding Provided by Cytokinetics to Each Organiz...
Cytokinetics Reports Fourth Quarter 2023 Financial Results
Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Improvements in All Secondary Endpoints
Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4...
Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to par...
Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Patient Advocacy Organizations to Support Communicat...
Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
New Data Show Treatment with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Resulted in Favorable Structural Remodeling, Improvements in Cardiac Function and Stabilization of Fibro...
Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
SOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an upcoming presentation at CMR 2024 taking place online and in person in Londo...
Novartis drops pursuit of Cytokinetics - WSJ
Novartis has backed away from its pursuit of Cytokinetics , the Wall Street Journal reported on Thursday, citing sources.
Novartis Pursuit of Cytokinetics Cools
Novartis has backed away from its pursuit of Cytokinetics.
Novartis in advanced talks to buy Cytokinetics
Cytokinetics Inc (NASDAQ: CYTK) popped another 15% on Monday following a report that Novartis AG (SWX: NOVN) is now in advanced talks to acquire the biopharmaceutical firm.
Novartis, Cytokinetics near merger: report
Novartis NOVN, +0.43% is close to acquiring Cytokinetics Inc. CYTK, +15.04% and its promising heart drug, according to a Wall Street Journal report Monday. A deal for South San Francisco-based Cytokin...
Novartis in advanced talks to buy Cytokinetics- WSJ
Swiss drugmaker Novartis is close to acquiring Cytokinetics and the deal could be finalized as soon as this week, the Wall Street Journal reported on Monday, citing people familiar with the matter.
Novartis in Advanced Talks to Buy Cytokinetics
Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug.
Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pre...
Cytokinetics CEO on shares soaring, heart drug Aficamten and American heart health
Robert Blum, Cytokinetics CEO, joins 'The Exchange' to discuss the biotech sector, the company's shares soaring on the latest trial of its heart drug, and more.
Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart Drug
Shares of Cytokinetics (CYTK) blasted off Wednesday after the firm announced positive results in a study of its experimental heart treatment.